A Phase lll Randomized Trial Investigating Bortezomib (NSC#681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Contact phone
Neelam Singh, PhD | 517.364.5591
Principal investigator
Dr. Renuka Gera, MD
Trial Category
Childhood Cancers
Trial SubCategory
Leukemia
Webform